Literature DB >> 18330843

Association of HAX1 deficiency with neurological disorder.

N Rezaei1, Z Chavoshzadeh, O R Alaei, I Sandrock, C Klein.   

Abstract

Severe congenital neutropenia (SCN) is a rare, heterogeneous, primary immunodeficiency disorder characterized by early onset of severe bacterial infections. We here describe a case of SCN associating neutropenia and neurodevelopmental delay. The girl was well until the age of 9 months, when she suffered from an episode of convulsion. Subsequently, she developed several episodes of superficial abscesses, oral ulcers and otitis media. Further work-up revealed severe congenital neutropenia caused by a homozygous mutation (R86X) in the antiapoptotic molecule HAX1. She also suffered from psychomotor retardation and recurrent seizures. This case illustrates that HAX1 deficiency may be associated with a neurological phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18330843     DOI: 10.1055/s-2008-1062704

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  12 in total

1.  Specific alterations of the HtrA2/HAX-1 ratio in the penumbra upon focal cerebral ischemia in mice.

Authors:  A Rami; A Langhagen
Journal:  Neurochem Res       Date:  2011-11-06       Impact factor: 3.996

2.  A novel HAX1 gene mutation in severe congenital neutropenia (SCN) associated with neurological manifestations.

Authors:  Muhammad Faiyaz-Ul-Haque; Abdullah Al-Jefri; Fouad Al-Dayel; Jalaluddin A K M Bhuiyan; Hala A Abalkhail; Randa Al-Nounou; Ahmed Al-Abdullatif; Monogaran S Pulicat; Ameera Gaafar; Ayodele A Alaiya; Iskra Peltekova; Syed H E Zaidi
Journal:  Eur J Pediatr       Date:  2010-02-25       Impact factor: 3.183

3.  Alterations in the expression of the anti-apoptotic factor HAX-1 upon seizures-induced hippocampal injury in the neonatal rat brain.

Authors:  A Rami; M Kim; J Niquet; A Langhagen
Journal:  Neurochem Res       Date:  2011-09-11       Impact factor: 3.996

4.  HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI.

Authors:  Kaan Boztug; Xiao-Qi Ding; Hans Hartmann; Lena Ziesenitz; Alejandro A Schäffer; Jana Diestelhorst; Dietmar Pfeifer; Giridharan Appaswamy; Sonja Kehbel; Thorsten Simon; Abdullah Al Jefri; Heinrich Lanfermann; Christoph Klein
Journal:  Am J Med Genet A       Date:  2010-12       Impact factor: 2.802

Review 5.  Genetic insights into congenital neutropenia.

Authors:  Christoph Klein; Karl Welte
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

6.  Hax-1 is rapidly degraded by the proteasome dependent on its PEST sequence.

Authors:  Bin Li; Qingsong Hu; Ranjie Xu; Haigang Ren; Erkang Fei; Dong Chen; Guanghui Wang
Journal:  BMC Cell Biol       Date:  2012-07-24       Impact factor: 4.241

7.  History of primary immunodeficiency diseases in iran.

Authors:  Asghar Aghamohammadi; Mostafa Moin; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

8.  Cardiac and renal malformations in a patient with sepsis and severe congenital neutropenia.

Authors:  Aziz Eghbali; Peyman Eshghi; Fatemeh Malek; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2010-06       Impact factor: 0.364

Review 9.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

Review 10.  ICON: the early diagnosis of congenital immunodeficiencies.

Authors:  John Routes; Mario Abinun; Waleed Al-Herz; Jacinta Bustamante; Antonio Condino-Neto; Maria Teresa De La Morena; Amos Etzioni; Eleonora Gambineri; Elie Haddad; Lisa Kobrynski; Francoise Le Deist; Shigeaki Nonoyama; Joao Bosco Oliveira; Elena Perez; Capucine Picard; Nima Rezaei; John Sleasman; Kathleen E Sullivan; Troy Torgerson
Journal:  J Clin Immunol       Date:  2014-03-12       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.